Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 September 2024Website:
http://kairospharma.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 20 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
KAPA Latest News
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit where he will be speaking with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024.
LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces that it has closed its initial public offering of 1,550,000 shares of common stock at an offering price of $4.00 per share. The gross proceeds to the Company from the offering were $6,200,000, before deducting underwriting discounts and commissions and other offering expenses. The Company's common stock began trading on the NYSE American LLC on September 16, 2024 under the symbol “KAPA.”
What type of business is Kairos Pharma?
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-?ß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer; and KROS 401, a cyclic peptide, which inhibits the IL-4 and IL-13 receptors. It also develops ENV 105, an antibody that targets CD105/Endoglin, which expressed in tumor cells and surrounding cells; and ENV 205, an antibody that targets mitochondrial DNA. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
What sector is Kairos Pharma in?
Kairos Pharma is in the Healthcare sector
What industry is Kairos Pharma in?
Kairos Pharma is in the Biotechnology industry
What country is Kairos Pharma from?
Kairos Pharma is headquartered in United States
When did Kairos Pharma go public?
Kairos Pharma initial public offering (IPO) was on 16 September 2024
What is Kairos Pharma website?
https://kairospharma.com
Is Kairos Pharma in the S&P 500?
No, Kairos Pharma is not included in the S&P 500 index
Is Kairos Pharma in the NASDAQ 100?
No, Kairos Pharma is not included in the NASDAQ 100 index
Is Kairos Pharma in the Dow Jones?
No, Kairos Pharma is not included in the Dow Jones index
When was Kairos Pharma the previous earnings report?
No data
When does Kairos Pharma earnings report?
The next expected earnings date for Kairos Pharma is 29 November 2024